Loading stock data…
RNAZ
$4.97-0.12 (-2.36%)
After Hours$5.11+0.14 (+2.82%)· Last close Jun 9
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TransCode Therapeutics, Inc. in the Healthcare sector is trading at $4.97 with a market capitalization of $5M. The stock is currently near its 52-week low of $3.82, remaining 46.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.97
Potential Downside
0%
Whystock Fair Value$4.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.79M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.93%
Volume
Today's trading volume
20,292
Recent News
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced Wednesday that it has successfully completed the Phase 1a dose-escalation clinical trial of its lead cancer therapeutic candidate, TTX-MC138. It met its primary safety objectives and demonstrated durable disease stabilization in patients with advanced metastatic cancer. The Boston-based clinical-stage company announced Wednesday that the drug candidate was well-tolerated, showing a complete absence of dose-limiting toxicities across all tested
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Car
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Hea
TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences
TransCode Therapeutics (RNAZ) said Wednesday it has agreed to buy biotechnology immuno-oncology comp
Wall Street Set to Open Higher Wednesday; Dow Rises on Japan Trade Deal
US stocks look set to open higher in Wednesday's trading session after the US announced a trade deal